Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge

被引：29

作者：

Yang, Ying ^{[1
]}

Yu, Yongfeng ^{[1
]}

Lu, Shun ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai 20030, Peoples R China

来源：

SCIENCE CHINA-LIFE SCIENCES | 2020年 / 63卷 / 10期

基金：

中国国家自然科学基金;

关键词：

immunotherapy; PD-1; PD-L1; inhibitors; lung cancer; OPEN-LABEL; CHECKPOINT INHIBITORS; CO-STIMULATION; PD-L1; BLOCKADE; EXPRESSION; NIVOLUMAB; DOCETAXEL; RESISTANCE; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.1007/s11427-019-1622-5

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Immune checkpoint inhibitors (ICIs), especially inhibitors of the PD-1/PD-L1 axis, have significantly affected the outcomes of patients with lung cancer. Nivolumab and pembrolizumab have been approved as PD-1 blocking antibodies, whereas atezolizumab, avelumab, and durvalumab are approved as PD-L1 blocking antibodies by the United States Food and Drug Administration. However, which patient may benefit the most and how to identify patients at risk of primary or acquired resistance has not been completely defined. Meanwhile, close attention has been paid to the ongoing international and domestic clinical trials in Chinese patients with lung cancer. This review aimed to provide deep insight into the effectiveness of PD-1/PD-L1 inhibitors in patients with lung cancer, including the current settings for varied disease status, the predictive biomarkers, the resistance to ICIs, and the ongoing clinical trials in Chinese patients.

引用

页码：1499 / 1514

页数：16

共 77 条

[61] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].

Rittmeyer, Achim ;

Barlesi, Fabrice ;

Waterkamp, Daniel ;

Park, Keunchil ;

Ciardiello, Fortunato ;

von Pawel, Joachim ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Kowalski, Dariusz M. ;

Dols, Manuel Cobo ;

Cortinovis, Diego L. ;

Leach, Joseph ;

Polikoff, Jonathan ;

Barrios, Carlos ;

Kabbinavar, Fairooz ;

Frontera, Osvaldo Aren ;

De Marinis, Filippo ;

Turna, Hande ;

Lee, Jong-Seok ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

He, Pei ;

Chen, Daniel S. ;

Sandler, Alan ;

Gandara, David R. .

LANCET, 2017, 389 (10066) :255-265

[62] Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing [J].

Rizvi, Hira ;

Sanchez-Vega, Francisco ;

La, Konnor ;

Chatila, Walid ;

Jonsson, Philip ;

Halpenny, Darragh ;

Plodkowski, Andrew ;

Long, Niamh ;

Sauter, Jennifer L. ;

Rekhtman, Natasha ;

Hollmann, Travis ;

Schalper, Kurt A. ;

Gainor, Justin F. ;

Shen, Ronglai ;

Ni, Ai ;

Arbour, Kathryn C. ;

Merghoub, Taha ;

Wolchok, Jedd ;

Snyder, Alexandra ;

Chaft, Jamie E. ;

Kris, Mark G. ;

Rudin, Charles M. ;

Socci, Nicholas D. ;

Berger, Michael F. ;

Taylor, Barry S. ;

Zehir, Ahmet ;

Solit, David B. ;

Arcila, Mina E. ;

Ladanyi, Marc ;

Riely, Gregory J. ;

Schultz, Nikolous ;

Hellmann, Matthew D. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (07) :633-+

[63] Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors [J].

Routy, Bertrand ;

Le Chatelier, Emmanuelle ;

Derosa, Lisa ;

Duong, Connie P. M. ;

Alou, Maryam Tidjani ;

Daillere, Romain ;

Fluckiger, Aurelie ;

Messaoudene, Meriem ;

Rauber, Conrad ;

Roberti, Maria P. ;

Fidelle, Marine ;

Flament, Caroline ;

Poirier-Colame, Vichnou ;

Opolon, Paule ;

Klein, Christophe ;

Iribarren, Kristina ;

Mondragon, Laura ;

Jacquelot, Nicolas ;

Qu, Bo ;

Ferrere, Gladys ;

Clemenson, Celine ;

Mezquita, Laura ;

Masip, Jordi Remon ;

Naltet, Charles ;

Brosseau, Solenn ;

Kaderbhai, Coureche ;

Richard, Corentin ;

Rizvi, Hira ;

Levenez, Florence ;

Galleron, Nathalie ;

Quinquis, Benoit ;

Pons, Nicolas ;

Ryffel, Bernhard ;

Minard-Colin, Veronique ;

Gonin, Patrick ;

Soria, Jean-Charles ;

Deutsch, Eric ;

Loriot, Yohann ;

Ghiringhelli, Francois ;

Zalcman, Gerard ;

Goldwasser, Francois ;

Escudier, Bernard ;

Hellmann, Matthew D. ;

Eggermont, Alexander ;

Raoult, Didier ;

Albiges, Laurence ;

Kroemer, Guido ;

Zitvogel, Laurence .

SCIENCE, 2018, 359 (6371) :91-+

[64] Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors [J].

Seban, Romain-David ;

Mezquita, Laura ;

Berenbaum, Arnaud ;

Dercle, Laurent ;

Botticella, Angela ;

Le Pechoux, Cecile ;

Caramella, Caroline ;

Deutsch, Eric ;

Grimaldi, Serena ;

Adam, Julien ;

Ammari, Samy ;

Planchard, David ;

Leboulleux, Sophie ;

Besse, Benjamin .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (05) :1147-1157

[65] STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma [J].

Skoulidis, Ferdinandos ;

Goldberg, Michael E. ;

Greenawalt, Danielle M. ;

Hellmann, Matthew D. ;

Awad, Mark M. ;

Gainor, Justin F. ;

Schrock, Alexa B. ;

Hartmaier, Ryan J. ;

Trabucco, Sally E. ;

Gay, Laurie ;

Ali, Siraj M. ;

Elvin, Julia A. ;

Singal, Gaurav ;

Ross, Jeffrey S. ;

Fabrizio, David ;

Szabo, Peter M. ;

Chang, Han ;

Sasson, Ariella ;

Srinivasan, Sujaya ;

Kirov, Stefan ;

Szustakowski, Joseph ;

Vitazka, Patrik ;

Edwards, Robin ;

Bufill, Jose A. ;

Sharma, Neelesh ;

Ou, Sai-Hong I. ;

Peled, Nir ;

Spigel, David R. ;

Rizvi, Hira ;

Aguilar, Elizabeth Jimenez ;

Carter, Brett W. ;

Erasmus, Jeremy ;

Halpenny, Darragh F. ;

Plodkowski, Andrew J. ;

Long, Niamh M. ;

Nishino, Mizuki ;

Denning, Warren L. ;

Galan-Cobo, Ana ;

Hamdi, Haifa ;

Hirz, Taghreed ;

Tong, Pan ;

Wang, Jing ;

Rodriguez-Canales, Jaime ;

Villalobos, Pamela A. ;

Parra, Edwin R. ;

Kalhor, Neda ;

Sholl, Lynette M. ;

Sauter, Jennifer L. ;

Jungbluth, Achim A. ;

Mino-Kenudson, Mari .

CANCER DISCOVERY, 2018, 8 (07) :822-835

[66] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[67] Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity [J].

Spranger, Stefani ;

Bao, Riyue ;

Gajewski, Thomas F. .

NATURE, 2015, 523 (7559) :231-U261

[68]

Squibb Bristol-Myers., 2018, Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial

[69] PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression [J].

Tang, Haidong ;

Liang, Yong ;

Anders, Robert A. ;

Taube, Janis M. ;

Qiu, Xiangyan ;

Mulgaonkar, Aditi ;

Liu, Xin ;

Harrington, Susan M. ;

Guo, Jingya ;

Xin, Yangchun ;

Xiong, Yahong ;

Nham, Kien ;

Silvers, William ;

Hao, Guiyang ;

Sun, Xiankai ;

Chen, Mingyi ;

Hannan, Raquibul ;

Qiao, Jian ;

Dong, Haidong ;

Peng, Hua ;

Fu, Yang-Xin .

JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (02) :580-588

[70] Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade [J].

Taube, Janis M. ;

Young, Geoffrey D. ;

McMiller, Tracee L. ;

Chen, Shuming ;

Salas, January T. ;

Pritchard, Theresa S. ;

Xu, Haiying ;

Meeker, Alan K. ;

Fan, Jinshui ;

Cheadle, Chris ;

Berger, Alan E. ;

Pardoll, Drew M. ;

Topalian, Suzanne L. .

CLINICAL CANCER RESEARCH, 2015, 21 (17) :3969-3976

← 1 2 3 4 5 6 7 8 →